Kymera Therapeutics (KYMR) – Analysts’ Recent Ratings Changes

A number of firms have modified their ratings and price targets on shares of Kymera Therapeutics (NASDAQ: KYMR) recently:

• 8/6/2026 – Kymera Therapeutics had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $135.00 price target on the stock.
• 8/6/2026 – Kymera Therapeutics had its “buy” rating reaffirmed by Citigroup Inc..
• 8/6/2026 – Kymera Therapeutics had its price target raised by Barclays PLC from $133.00 to $139.00. They now have an “overweight” rating on the stock.
• 8/5/2026 – Kymera Therapeutics had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $125.00 price target on the stock.
• 7/30/2026 – Kymera Therapeutics is now covered by Deutsche Bank Aktiengesellschaft. They set a “hold” rating and a $120.00 price target on the stock.
• 7/28/2026 – Kymera Therapeutics had its price target raised by Guggenheim from $125.00 to $135.00. They now have a “buy” rating on the stock.
• 7/17/2026 – Kymera Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/16/2026 – Kymera Therapeutics had its price target raised by Mizuho from $120.00 to $140.00. They now have an “outperform” rating on the stock.
• 7/13/2026 – Kymera Therapeutics was downgraded by Royal Bank Of Canada from “outperform” to “sector perform”. They now have a $115.00 price target on the stock, up from $106.00.
• 6/30/2026 – Kymera Therapeutics had its price target raised by Bank of America Corporation from $110.00 to $125.00. They now have a “buy” rating on the stock.
• 6/29/2026 – Kymera Therapeutics had its price target raised by B. Riley Financial, Inc. from $117.00 to $155.00. They now have a “buy” rating on the stock.
• 6/29/2026 – Kymera Therapeutics had its price target raised by Truist Financial Corporation from $116.00 to $136.00. They now have a “buy” rating on the stock.
• 6/26/2026 – Kymera Therapeutics had its price target raised by Canaccord Genuity Group Inc. from $106.00 to $129.00. They now have a “buy” rating on the stock.
• 6/25/2026 – Kymera Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $134.00 price target on the stock.
• 6/8/2026 – Kymera Therapeutics was given a new $97.00 price target by Loop Capital.
• 6/8/2026 – Kymera Therapeutics had its “buy” rating reaffirmed by Brookline Capital Markets.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, Director Bvf Partners L. P/Il sold 1,578,800 shares of the firm’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $106.50, for a total value of $168,142,200.00. Following the transaction, the director owned 240,123 shares of the company’s stock, valued at $25,573,099.50. This trade represents a 86.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Noah Goodman sold 3,389 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $114.29, for a total value of $387,328.81. Following the completion of the sale, the insider directly owned 47,179 shares in the company, valued at approximately $5,392,087.91. This trade represents a 6.70% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 3,607,813 shares of company stock worth $387,818,004. 15.98% of the stock is owned by insiders.

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.